| Industry: Pharmaceuticals |
|
| 1 |
Johnson & Johnson
|
13 |
12 |
12 |
122,200 |
6 |
| 2 |
Pfizer
|
18 |
8 |
15 |
98,000 |
-8 |
| 3 |
Merck
|
3 |
4 |
43 |
60,000 |
-2 |
| 4 |
Abbott Laboratories
|
-1 |
10 |
27 |
66,663 |
12 |
| 5 |
Wyeth
|
8 |
8 |
13 |
50,060 |
1 |
| 6 |
Bristol-Myers Squibb
|
-5 |
3 |
20 |
43,000 |
0 |
| 7 |
Eli Lilly
|
6 |
6 |
-5 |
41,500 |
-3 |
| 8 |
Amgen
|
15 |
18 |
-13 |
20,050 |
22 |
| 9 |
Schering-Plough
|
-1 |
6 |
15 |
33,500 |
3 |
| 10 |
Genzyme
|
N.A. |
19 |
-13 |
9,000 |
10 |
| 11 |
Allergan
|
N.A. |
22 |
11 |
6,772 |
34 |
| 12 |
Gilead Sciences
|
N.A. |
35 |
24 |
2,515 |
32 |
| 13 |
Forest Laboratories
|
22 |
29 |
24 |
5,050 |
-2 |
| 14 |
Hospira
|
N.A. |
N.A. |
-22 |
13,000 |
0 |
| 15 |
Biogen Idec
|
N.A. |
29 |
9 |
3,750 |
12 |
| 16 |
King Pharmaceuticals
|
N.A. |
N.A. |
-6 |
2,803 |
0 |
| 17 |
Watson Pharmaceuticals
|
N.A. |
1 |
-20 |
5,830 |
52 |
| 18 |
NBTY
|
22 |
21 |
156 |
10,900 |
-3 |
| 19 |
Cephalon
|
N.A. |
13 |
9 |
2,895 |
0 |
From the April 30th, 2007 issue
|
| Most profitable companies |
| Fortune 500 methodology |
| Included in the survey are U.S. incorporated companies filing financial statements with a government agency. This includes private companies... (more)
|
|
